Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2810-2816

  Ross, Ashley E ^a   Loeb, Stacy ^a   Landis, Patricia ^a   Partin, Alan W ^a   Epstein, Jonathan I ^a   Kettermann, Anna ^a   Feng, Zhaoyong ^a   Carter, H Ballentine ^a   Walsh, Patrick C ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BIOPSY; BLOOD; DISEASE COURSE; HEALTH SURVEY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77956396162     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.7311     Document Type: Article

References (17)

1. Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878, 2003 (Pubitemid 36833878)
2. Klotz L: Active surveillance for prostate cancer: For whom? J Clin Oncol 23:8165-8169, 2005
3. Ng MK, Van As N, Thomas K, et al: Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity versus PSA doubling time. BJU Int 103:872-876, 2009
4. Soloway MS, Soloway CT, Williams S, et al: Active surveillance; a reasonable management alternative for patients with prostate cancer: The Miami experience. BJU Int 101:165-169, 2008 (Pubitemid 350294039)
5. Carter HB, Ferrucci L, Kettermann A, et al: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-1527, 2006 (Pubitemid 44680903)
6. Carter HB, Morrell CH, Pearson JD, et al: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52:3323-3328, 1992
7. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
8. van den Bergh RC, Roemeling S, Roobol MJ, et al: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55:1-8, 2009
9. Network NCC: Prostate cancer guideline v1.2009. http://www.nccn.org
10. Carter HB, Kettermann A, Warlick C, et al: Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 178:2359-2364, 2007; discussion 2364-2365
11. Carter HB, Epstein JI, Chan DW, et al: Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277:1456-1460, 1997 (Pubitemid 27208888)
12. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003 (Pubitemid 36132976)
13. Stephenson AJ, Kattan MW, Eastham JA, et al: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300-4305, 2009
14. Al Otaibi M, Ross P, Fahmy N, et al: Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113:286-292, 2008
15. Warlick C, Trock BJ, Landis P, et al: Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98:355-357, 2006 (Pubitemid 43338215)
16. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
17. Loeb S, Sutherland DE, D'Amico AV, et al: PSA velocity is associated with Gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness. Urology 72:1116-1120, 2008; discussion 1120